FDA issues priority review voucher for EMCITATE (tiratricol)
The FDA announced that EMCITATE (tiratricol), approved September 28, 2026, manufactured by Rare Thyroid Therapeutics International AB, meets the criteria for a priority review voucher. The tablet is indicated for treating peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 deficiency (Allan-Herndon-Dudley syndrome).
Primary source
Federal Register notice, October 28, 2026
Issuance of Priority Review Voucher; Rare Pediatric Disease Product; EMCITATE (Tiratricol)
Read the source: Issuance of Priority Review Voucher; Rare Pediatric Disease Product; EMCITATE (Tiratricol) federalregister.gov
Machine-summarized from the source above; not independently reported. How we use automation